U.S. Markets close in 38 mins
  • S&P 500

    3,755.34
    -64.38 (-1.69%)
     
  • Dow 30

    30,795.02
    -475.07 (-1.52%)
     
  • Nasdaq

    12,691.90
    -305.85 (-2.35%)
     
  • Russell 2000

    2,151.56
    -56.23 (-2.55%)
     
  • Crude Oil

    64.12
    +2.84 (+4.63%)
     
  • Gold

    1,694.00
    -21.80 (-1.27%)
     
  • Silver

    25.33
    -1.05 (-3.99%)
     
  • EUR/USD

    1.1967
    -0.0100 (-0.8258%)
     
  • 10-Yr Bond

    1.5500
    +0.0800 (+5.44%)
     
  • Vix

    28.68
    +2.01 (+7.54%)
     
  • GBP/USD

    1.3887
    -0.0066 (-0.4708%)
     
  • USD/JPY

    107.9250
    +0.9230 (+0.8626%)
     
  • BTC-USD

    48,044.72
    -2,449.47 (-4.85%)
     
  • CMC Crypto 200

    962.92
    -24.29 (-2.46%)
     
  • FTSE 100

    6,650.88
    -24.59 (-0.37%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

We Think Relmada Therapeutics (NASDAQ:RLMD) Can Afford To Drive Business Growth

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.

So should Relmada Therapeutics (NASDAQ:RLMD) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

View our latest analysis for Relmada Therapeutics

How Long Is Relmada Therapeutics' Cash Runway?

You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. In September 2020, Relmada Therapeutics had US$123m in cash, and was debt-free. In the last year, its cash burn was US$25m. So it had a cash runway of about 4.8 years from September 2020. There's no doubt that this is a reassuringly long runway. The image below shows how its cash balance has been changing over the last few years.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Relmada Therapeutics' Cash Burn Changing Over Time?

Relmada Therapeutics didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. In fact, it ramped its spending strongly over the last year, increasing cash burn by 124%. That sort of ramp in expenditure is no doubt intended to generate worthwhile long term returns. While the past is always worth studying, it is the future that matters most of all. So you might want to take a peek at how much the company is expected to grow in the next few years.

How Easily Can Relmada Therapeutics Raise Cash?

While Relmada Therapeutics does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Companies can raise capital through either debt or equity. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

Since it has a market capitalisation of US$557m, Relmada Therapeutics' US$25m in cash burn equates to about 4.6% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.

Is Relmada Therapeutics' Cash Burn A Worry?

It may already be apparent to you that we're relatively comfortable with the way Relmada Therapeutics is burning through its cash. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. While we must concede that its increasing cash burn is a bit worrying, the other factors mentioned in this article provide great comfort when it comes to the cash burn. After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. On another note, Relmada Therapeutics has 3 warning signs (and 2 which are significant) we think you should know about.

Of course Relmada Therapeutics may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.